Exploring the mechanistic basis for altered peripheral B cell selection in SLE

探索 SLE 中外周 B 细胞选择改变的机制基础

基本信息

  • 批准号:
    8732775
  • 负责人:
  • 金额:
    $ 30.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

In surprising findings from the previous funding period of the UChicago ACE we found that systemic lupus erythematous (SLE) patients generated higher-affinity and more potently neutralizing anti-influenza antibodies (manuscript in preparation). We have also demonstrated this tendency in the Mrl-lpr/lpr mouse model of SLE. These findings suggest one of two primary hypotheses that we believe are of central importance to understanding the cause of SLE. First, there is the possibility that people who make higher affinity antibodies in general are also at a higher risk for lupus. All people likely make autoantibody responses from time to time. However, individuals that are prone to make high affinity antibodies during any immune response may make higher affinity and therefore pathological autoantibodies on occasion that with epitope spreading will result in SLE. The second possibility is that autoimmunity may improve antibody responses. Thus higher-affinity and concomitantly autoimmunity are selected together, increasing the risk for SLE. That is the autoimmune repertoire, or other features associated with autoimmunity such as inflammation, enables more effective antibody responses. In this renewal application, we propose to test various hypotheses to reveal the mechanisms by which SLE patients mount more effective humoral immune responses to influenza and other vaccines. We also noted that unlike control subject antibodies that were somewhat autoreactive, those from SLE patients were uniquely reactive to self-antigens without being polyreactive. These findings suggest that in SLE patients, selection against polyreactivity during peripheral immune responses is intact, supporting a model for lupus pathology in which high-affinity autoantibodies are generated in self-antigen specific responses. In Specific Aim 1 we will perform experiments to explore this hypothesis. In Specific Aims 2 and 3 we will explore the mechanistic basis for generating high affinity, and conversely, autoimmune-prone responses in SLE patients and controls (Aim 2) or in mouse models of autoimmunity (Aim 3). These experiments will provide insight into why autoimmunity might be maintained in the general population.
在芝加哥大学ACE的前一个资助期的令人惊讶的发现中,我们发现系统性狼疮 SLE患者产生更高亲和力和更强中和性的抗流感病毒抗体, 抗体(手稿在准备中)。我们还在MRL-lpr/lpr小鼠中证明了这种趋势 SLE模型这些发现表明了我们认为是核心的两个主要假设之一 了解SLE的病因。首先,有一种可能性, 亲和性抗体通常也具有较高的狼疮风险。所有人都可能产生自身抗体 不时的回应。然而,在任何情况下都倾向于产生高亲和力抗体的个体, 免疫应答可能产生更高亲和力,因此有时会产生病理性自身抗体, 表位扩散将导致SLE。第二种可能性是自身免疫可以提高抗体水平, 应答因此,更高的亲和力和伴随的自身免疫性被一起选择,增加了 SLE。这是自身免疫性库,或与自身免疫相关的其他特征,如 炎症,使更有效的抗体反应。在这次更新申请中,我们建议测试 各种假说揭示了系统性红斑狼疮患者获得更有效体液免疫的机制 流感疫苗和其他疫苗。我们还注意到,与对照受试者不同, 有些自身反应性,来自SLE患者的那些仅对自身抗原反应,而不是多反应性的。 这些发现表明,在SLE患者中,外周血中对多反应性的选择, 免疫反应是完整的,支持狼疮病理模型,其中高亲和力自身抗体是 在自身抗原特异性反应中产生。在具体目标1中,我们将进行实验来探索这一点 假说.在具体目标2和3中,我们将探索产生高亲和力的机制基础, 相反,在SLE患者和对照组(Aim 2)或SLE小鼠模型中, 自身免疫(目的3)。这些实验将提供深入了解为什么自身免疫可能维持在 一般人。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Patrick Christopher Wilson其他文献

Patrick Christopher Wilson的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Patrick Christopher Wilson', 18)}}的其他基金

Monoclonal Antibody Technology Core
单克隆抗体技术核心
  • 批准号:
    10468074
  • 财政年份:
    2012
  • 资助金额:
    $ 30.81万
  • 项目类别:
Monoclonal Antibody Technology Core
单克隆抗体技术核心
  • 批准号:
    10223126
  • 财政年份:
    2012
  • 资助金额:
    $ 30.81万
  • 项目类别:
COBRE: OK MED RES FOUND: P2: REGULATION OF ANTIBODY PRODUCTION TO A AUTOANTIGEN
COBRE:确定医学研究发现:P2:自身抗原抗体产生的调节
  • 批准号:
    8168450
  • 财政年份:
    2010
  • 资助金额:
    $ 30.81万
  • 项目类别:
The Role of Natural Human Anergic B cells in Systemic Lupus Erythematosus Patholo
天然人类无反应性 B 细胞在系统性红斑狼疮病理中的作用
  • 批准号:
    7684353
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
Autoimmunity Lymphocyte Repertoire Core (ALRC)
自身免疫淋巴细胞库核心 (ALRC)
  • 批准号:
    7688953
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
主要项目:乳糜泻抗体和自身抗体反应的 B 细胞反应
  • 批准号:
    10631980
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
Early Plasma Cells as a Source of Anthrax-Neutralizing Antibodies
早期浆细胞作为炭疽中和抗体的来源
  • 批准号:
    7696156
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
主要项目:乳糜泻抗体和自身抗体反应的 B 细胞反应
  • 批准号:
    10413990
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
Principal Project: B cell response underlying Celiac disease antibody and autoantibody responses
主要项目:乳糜泻抗体和自身抗体反应的 B 细胞反应
  • 批准号:
    10189480
  • 财政年份:
    2009
  • 资助金额:
    $ 30.81万
  • 项目类别:
The origin and consequences of receptor editing and allelic-inclusion.
受体编辑和等位基因包含的起源和后果。
  • 批准号:
    8115033
  • 财政年份:
    2008
  • 资助金额:
    $ 30.81万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 30.81万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 30.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了